Exact Sciences

Exact Sciences


Loading Stocks


$0.92 (-1.30%)








Exact Sciences Corporation is a global cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection. It offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. It is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.



Prior close


Today's high


Today's low


52 Week high


52 Week low

Where Will Exact Sciences Be in 5 Years?
Newsfeed image icon
Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs
Newsfeed image icon
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
Newsfeed image icon
The 3 Best Cathie Wood Stocks to Buy Now: September 2023
Newsfeed image icon
View disclosures

Start Your Investing Journey At MoneyLion

Access fully managed portfolios to help you invest towards your future, without the heavy lifting.

Market Data

Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.